1530 Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
3SBio Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$6.27 |
52 Week High | HK$7.97 |
52 Week Low | HK$4.91 |
Beta | 0.73 |
11 Month Change | -1.57% |
3 Month Change | 4.85% |
1 Year Change | -18.47% |
33 Year Change | -34.69% |
5 Year Change | -55.97% |
Change since IPO | -36.28% |
Recent News & Updates
Recent updates
Shareholder Returns
1530 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 3.0% | 0.2% | -3.3% |
1Y | -18.5% | -32.5% | 0.2% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned -31.1% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned 1.3% over the past year.
Price Volatility
1530 volatility | |
---|---|
1530 Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 7.0% |
10% most volatile stocks in HK Market | 14.8% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1530 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1530's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 5,411 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
1530 fundamental statistics | |
---|---|
Market cap | HK$14.84b |
Earnings (TTM) | HK$1.66b |
Revenue (TTM) | HK$8.40b |
8.9x
P/E Ratio1.8x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1530 income statement (TTM) | |
---|---|
Revenue | CN¥7.82b |
Cost of Revenue | CN¥1.17b |
Gross Profit | CN¥6.64b |
Other Expenses | CN¥5.09b |
Earnings | CN¥1.55b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.65 |
Gross Margin | 84.98% |
Net Profit Margin | 19.82% |
Debt/Equity Ratio | 29.1% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield36%
Payout RatioDoes 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks3SBio dividend dates | |
---|---|
Ex Dividend Date | Jul 22 2024 |
Dividend Pay Date | Aug 05 2024 |
Days until Ex dividend | 24 days |
Days until Dividend pay date | 38 days |
Does 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks